A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma

• Published in: Journal of clinical neuroscience 2020-04, Vol.74, p.187-193
• Main Authors: Rudnick, Jeremy D., Sarmiento, J. Manuel, Uy, Benjamin, Nuno, Miriam, Wheeler, Christopher J., Mazer, Mia J., Wang, Hongqiang, Hu, Jethro L., Chu, Ray M., Phuphanich, Surasak, Black, Keith L., Yu, John S.
• Format: Article
• Language: English
• Subjects: Anaplastic astrocytoma (AA); Anaplastic oligodendroglioma (AO); Gliadel Wafer; Glioblastoma (GBM); Overall survival (OS); Progression-free survival (PFS); Vaccine therapy
• ISSN: 0967-5868; 1532-2653
• DOI: 10.1016/j.jocn.2020.03.006

•High grade gliomas are associated with a poor prognosis, even with surgery followed by radiation therapy and chemotherapy.•Gliadel Wafer treatments have shown improvements in overall survival in recurrent and newly-diagnosed malignant gliomas.•Autologous dendritic cell therapies have previously shown a strong immune response in patients with malignant gliomas.•There is no synergy of local chemotherapy and immunotherapy to improve survival in patients with high grade gliomas. High grade gliomas are associated with poor prognosis and high mortality. Conventional treatments and management of high grade gliomas have shown little improvement in 5-year overall survival. This phase I trial evaluated the safety, immunogenicity, and potential synergy of surgical resection with Gliadel Wafer implantation, followed by autologous tumor lysate-pulsed dendritic cell (DC) vaccine in patients with malignant glioma. Primary end points of this study were safety and surrogate markers of immunogenicity, overall survival, and progression free survival. Following surgical resection, Gliadel Wafers were placed along the resection cavity. Patients subsequently received intradermal injections of autologous tumor lysate-pulsed DC vaccines 3 times at 2 week intervals. Treatment response was evaluated clinically and through MRI at regular intervals. Twenty-eight patients received Gliadel Wafers and DC vaccination: 11 newly diagnosed (8 glioblastoma [GBM], 2 anaplastic astrocytoma [AA], and 1 anaplastic oligodendroglioma [AO]) and 17 recurrent (15 GBMs, 1 AA, and 1 AO) high grade gliomas. Immunogenicity data was collected for 20 of the 28 patients. Five of 20 patients showed elevated IFN-γ responses following vaccination. Median progression-free survival and overall survival for all GBM patients in the trial from the start of vaccination were 3.6 months and 16.9 months respectively. Comparisons between vaccine responders and non-vaccine responders were not statistically significant. Adjuvant autologous dendritic cells pulsed with tumor-lysate following resection and Gliadel Wafer placement is safe, elicits modest immunogenicity and shows similar clinical outcomes in patients who had DC vaccination in previous studies.